OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Galligan on Transplant Eligibility and Subsequent Treatments in Multiple Myeloma

October 20th 2020

Derek C. Galligan, MD, discusses transplant eligibility in determining subsequent treatment for patients with multiple myeloma.

Dr. Azad on the Design of the ARCHES Trial in mHSPC

October 20th 2020

Arun Azad, PhD, discusses the design of the phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer.

Dr. Kantoff on the Rationale to Evaluate VERU-111 in mCRPC

October 20th 2020

Philip W. Kantoff, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Dr. Hussain on the Need for Effective Treatment in Nonmetastatic CRPC

October 20th 2020

Maha Hussain, MD, FACP, FASCO, discusses the need for treatment that elicits an overall survival benefit in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Jackson on VEGF Versus PARP Inhibitors in Recurrent Ovarian Cancer

October 19th 2020

Amanda L. Jackson, MD, discusses choosing between VEGF inhibitors and PARP inhibitors in the treatment of patients with recurrent platinum-sensitive ovarian cancer.

Dr. Shore on the Design of the HERO Trial With Relugolix in Advanced Prostate Cancer

October 19th 2020

Neal D. Shore, MD, FACS, discusses the design of the phase 3 HERO trial in patients with advanced prostate cancer.

Dr. Bhat on the FDA Approval of Acalabrutinib in CLL

October 19th 2020

Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.

Dr. Masarova on Future Research in MPNs

October 19th 2020

Lucia Masarova, MD, discusses future research efforts in myeloproliferative neoplasms.

Dr. Paplomata on the Role of Tucatinib/Trastuzumab/Capecitabine in HER2+ Metastatic Breast Cancer

October 19th 2020

Elisavet Paplomata, MD, discusses the role of tucatinib in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.

Dr. Azad on the Importance of Germline Testing in CRC

October 19th 2020

Nilofer Saba Azad, MD, discusses the significance of germline testing in colorectal cancer.

Dr. Nagle on Sequencing Challenges in Multiple Myeloma

October 19th 2020

Sarah Nagle, MD, discusses sequencing challenges in multiple myeloma.

Dr. Maki on the Utility of Tazemetostat in Epithelioid Sarcoma

October 19th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of tazemetostat in epithelioid sarcoma.

Dr. Brar on the Need to Identify Biomarkers in HCC

October 19th 2020

Gagandeep Brar, MD, discusses the need to identify biomarkers in hepatocellular carcinoma.

Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis

October 16th 2020

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Dr. Silbermann on the CASTOR Trial in Relapsed/Refractory Myeloma

October 16th 2020

Rebecca Silbermann, MD, MMS, discusses the phase 3 CASTOR trial in relapsed/refractory multiple myeloma.

Dr. McDermott on the Design of the DASL-HiCAP Trial in High-Risk Prostate Cancer

October 16th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the design of the DASL-HiCAP trial in high-risk prostate cancer.

Dr. O’Regan on the Role of Therapy Escalation in HER2+ Breast Cancer

October 16th 2020

Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.

Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

October 16th 2020

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.

Dr. Sun on First-Line Treatment Challenges in Gastric Cancer

October 16th 2020

Weijing Sun, MD, FACP, discusses remaining challenges in the first-line treatment of patients with gastric cancer.

Dr. Aggarwal on Investigational Biomarkers in Lung Cancer

October 16th 2020

Charu Aggarwal, MD, MPH, discusses investigational biomarkers in lung cancer.